NovaDx and Tera Biotechnology see disease marker breakthrough:
This article was originally published in Clinica
US companies NovaDx and Tera Biotechnology have signed a letter of intent jointly to develop a technology to shorten the time taken by researchers to identify disease markers in blood. The companies believe they can reduce the time from a current five-to-ten years to just months. The technology would have direct application in diagnostics product development, for which the two enterprises will form a separate company. The research will be conducted in NovaDx' San Diego laboratories while Tera, based in the same city, will provide gene cloning technology. The agreement should be signed by August 1st, 1995.